Belite Bio Receives IND Approval From FDA to Begin Clinical Trials With LBS-008 for Macular Degeneration and Stargardt Disease

Belite Bio Receives IND Approval From FDA to Begin Clinical Trials With LBS-008 for Macular Degeneration and Stargardt Disease

 Belite Bio, a subsidiary of Lin Bioscience focused on targeting untreatable age-related metabolic diseases, announced that the U.S. FDA approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967) for the treatment of atrophic Age-related Macular...

Pin It on Pinterest